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Abstract
Introduction Hydroxyethyl starch (HES) solutions are widely
used for volume replacement therapy but are also known to
compromise coagulation, impair renal function and increase
long-term mortality. To test the hypotheses that HES 130/0.4
has fewer adverse effects than HES 200/0.5 and exerts anti-
inflammatory properties, we compared the effects of HES 130/
0.4, HES 200/0.5 and saline on in vitro haemostasis and pro-
inflammatory platelet function.
Methods Whole blood samples from healthy volunteers were
mixed with 6% HES 130/0.4, 10% HES 200/0.5, or normal
saline to achieve a final haemodilution rate of 10% or 40%.
Haemostatic capacity was characterised by
thromboelastography (ROTEM) and measurement for FXIIIa
activity. Platelet activation and pro-inflammatory platelet
functions were characterised by flow cytometry measuring the
platelet activation marker CD62P and binding of fibrinogen to
platelets as well as the formation of heterotypic platelet-
leukocyte conjugates.
Results Compared with saline, HES 130/0.4 dose-dependently
impaired formation and firmness of the fibrin clot but did not
affect the fibrin crosslinking activity of FXIIIa. At 40% but not at
10% haemodilution rate, HES 200/0.5 also increased platelet
fibrinogen binding and both HES solutions increased
expression of CD62P, the main receptor for platelet-leukocyte
adhesion. HES 130/0.4 but not HES 200/0.5 increased
formation of platelet-neutrophil conjugates and, to a lesser
degree, platelet-monocyte conjugates.
Conclusions Our data demonstrate that HES 130/0.4 has
similar adverse effects as HES 200/0.5. In particular, both types
of HES impair coagulation capacity and stimulate, rather than
attenuate, pro-inflammatory platelet function.
Introduction
Hydroxyethyl starch (HES) solutions are widely used for vol-
ume replacement therapy in anaesthesiology and intensive
care medicine despite a lack of clinical superiority over crystal-
loid solutions in these patients by meta-analysis [1] or in large
clinical trials [2]. HES, moreover, is associated with adverse
effects such as impairment of coagulation [3], renal function
[4] and long-term mortality [2]. Increased bleeding risk after
infusion of HES is believed to be due not only to haemodilution
but also to direct and indirect effects of HES on components
of the haemostatic systems: inhibition of blood platelet func-
tion [5,6], decrease of coagulation factors such as Von Wille-
brand factor and factor VIII [3], decrease of plasma fibrinogen
level or enhanced fibrinolysis [7-9]. However, the detailed
pathomechanisms are not clear. Adverse effects of HES on
haemostasis were found to depend on the in vivo molecular
weight and the degree of hydroxylation [3,10,11]. The most
modern HES with a mean molecular weight of 130 kDa and a
mean degree of substitution of 0.4 (HES 130/0.4) is therefore
claimed to have fewer adverse effects on haemostasis and
renal function than formerly used HES solutions [12,13]. Fur-
thermore, HES 130/0.4 has been reported to have some anti-
inflammatory effects that might provide benefit to patients with
systemic inflammation and sepsis [14-16]. Recent ex vivo
studies, however, have shown that HES 130/0.4 does still
impair haemostasis and platelet function and led to severe
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blood loss in an animal model of acute liver bleeding com-
pared with Ringer lactate [17-19].
To test the hypotheses that HES 130/0.4 causes less coagu-
lopathy than HES 200/0.5 and exerts some anti-inflammatory
activity, we studied the effects of HES 130/0.4, HES 200/0.5
and saline on in vitro haemostasis by ROTEM thromboelastog-
raphy (Pentapharm GmbH, Munich, Germany). Furthermore,
we measured surface expression of the platelet granule mem-
brane protein CD62P as well as the adhesion of platelets to
leukocytes as markers of pro-inflammatory platelet function
[20,21].
Materials and methods
After approval by the local ethics committee and written
informed consent, blood samples from 14 healthy male volun-
teers (22 to 61 years old) were obtained by a clean puncture
of an antecubital vein and were anticoagulated by either
sodium citrate (final concentration of 10.6 mM) or recom-
binant hirudin (50 μg/mL). Blood samples were then diluted
with HES 130/0.4 (Voluven 6%; Fresenius Kabi AG, Bad
Homburg, Germany), HES 200/0.5 (HAES sterile 10%; Fre-
senius Kabi AG) or sterile saline to obtain haemodilution rates
of 10% and 40%. Thus, the final molar concentrations of HES
130/0.4 and HES 200/0.5 in the diluted blood samples were
comparable. The samples were kept under gentle agitation for
15 minutes at 37°C prior to further analysis.
ROTEM analysis and FXIII activity measurement
ROTEM was carried out according to the manufacturer's
instructions in samples of citrated blood using equipment and
test kits provided by Pentapharm GmbH. The following tests
were performed: EXTEM® to measure clot formation triggered
by the activation of the extrinsic, tissue factor-dependent path-
way and FIBTEM®, which is based on EXTEM but contains
cytochalasin D to inhibit the contribution of platelets to meas-
ure the contribution of fibrin(ogen) to the clot firmness [22].
ROTEM provides a continuous measure of the clot firmness,
the amplitude of which is given in millimetres. By digital data
processing, the following typical variables are obtained: clot-
ting time (CT), which is the time from start of measurement
until the onset of clotting; clot formation time (CFT), which is
the time between onset of clotting and the moment when clot
firmness reaches an amplitude of 20 mm; the maximum clot
formation rate (CFR), which is the maximum rise in clot firm-
ness and is given as angle α; and maximum clot firmness
(MCF), which corresponds to the maximum amplitude of the
curve. If fibrinolysis occurs, MCF is reduced with time, and a
lysis rate can be calculated as a percentage of MCF.
The activity of factor FXIIIa, which stabilises the haemostatic
clot by crosslinking fibrin fibres [23,24], was determined in
plasma samples obtained from blood after dilution with HES or
saline. The activity was measured using a fluorogenic sub-
strate (Fluorescent FXIII Assay; Zedira GmbH, Darmstadt,
Germany). The activities are given as a percentage related to
plasma samples obtained from undiluted blood.
Flow cytometry
Flow cytometry was used to study the effects of HES on mark-
ers of platelet activation (that is, the surface expression of
CD62P and the binding of fibrinogen to its activated receptor
on the platelet surface [αIIbβ3 integrin]) as well as the adhesion
of platelets to leukocytes [25,26]. To minimise platelet-platelet
aggregation, the samples were diluted 1:5 with calcium-free
Hanks' balanced salt solution (HBSS). Platelet activation stud-
ies were done in hirudinised blood samples with adenosine
diphosphate (ADP) (5 μM), a thrombin receptor antagonist
(thrombin receptor-activating peptide, or TRAP) (25 μM) or
saline as control. After the samples were incubated for 5 min-
utes at 37°C, aliquots were mixed with anti-CD42a-PE and
one of the following fluorescence-labelled antibodies: anti-
CD62P-FITC, anti-CD45-FITC (both from Becton Dickinson,
Heidelberg, Germany) or anti-fibrinogen-FITC (WAK-Chemie,
Bad Sodenam Taunus, Germany; all antibody dilutions were 5
μL/100 μL). All samples were incubated for 15 minutes in the
dark at room temperature.
Samples labelled with CD62P-FITC antibody were mixed with
1 mL of phosphate-buffered saline (PBS) containing 1% para-
formaldehyde (PFA) for cell fixation and kept on ice until flow
cytometry analysis (FACScan with CellQuest Pro software;
Becton Dickinson). Samples stained with fibrinogen-FITC anti-
body were mixed with 2.5 mL of HBSS. After centrifugation for
8 minutes at 350 g, the cells were resuspended in 0.5 mL of
PBS/1% PFA and kept on ice until the flow cytometry
measurement.
For the detection of platelet-leukocyte interactions, erythro-
cytes were lysed with prewarmed FACS Lysing solution (Bec-
ton Dickinson) for 5 minutes at 37°C. The reaction was
stopped by the addition of 1.5 mL of HBSS. After centrifuga-
tion, the cells were resuspended in 0.5 mL of PBS/1% PFA
and kept on ice until analysis.
Platelets were identified according to their forward and side-
ward light scatter characteristics and binding of the platelet-
specific anti-CD42a and were analysed for anti-CD62P or
fibrinogen binding. Neutrophils, lymphocytes and monocytes
were identified by their scatter characteristics and the binding
of the leukocyte-specific anti-CD45 and analysed for CD42a
as a measure for the formation of platelet-leukocyte conju-
gates. Fluorescence-labelled isotype-matched IgG antibodies
were used to correct for non-specific binding of the specific
antibodies.
Statistics
Results are given as mean ± standard error of mean. All data
were examined for normal distribution using the Shapiro-Wilk
test. Significances of normally distributed data were identifiedAvailable online http://ccforum.com/content/13/6/R208
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using analysis of variance for repeated measures followed by
post hoc comparisons using the t test for paired samples. The
level of significance was adjusted according to Bonferroni cor-
rection. Statistical analyses of non-normally distributed data
were performed by the non-parametric Friedman test following
the Wilcoxon rank sum test adjusted according to Bonferroni-
Holm.
Results
ROTEM and FXIIIa
As shown in Figure 1, the effect of HES 130/0.4 and HES
200/0.5 on CT was not significantly different from that of
saline (Figure 1a). With respect to the other ROTEM variables,
both types of HES had significant effects compared with
saline. At a haemodilution rate of 40% with HES 130/0.4, CFT
was nearly doubled (Figure 1b), and MCF in EXTEM and
FIBTEM were reduced by about 20% and 65%, respectively,
compared with saline (Figure 1c, d). There was also a signifi-
cant reduction in FIBTEM-MCF at a haemodilution rate of 10%
Figure 1
Effects of hydroxyethyl starch (HES) 130/0.4 and HES 200/0.5 on in vitro clot formation in comparison with saline after haemodilution rates of 10%  (white) or 40% (grey) with either HES solution or saline (Control) Effects of hydroxyethyl starch (HES) 130/0.4 and HES 200/0.5 on in vitro clot formation in comparison with saline after haemodilution rates of 10% 
(white) or 40% (grey) with either HES solution or saline (Control). Clotting time (a), clot formation time (b) and maximum clot firmness (MCF) in 
EXTEM (c) as well as MCF in FIBTEM (d) were determined by ROTEM. Data are given as mean ± standard error of the mean obtained from six iden-
tical experiments. Significant differences between saline and HES 130/0.4 or HES 200/0.5: *P < 0.05, **P < 0.005, ***P < 0.001.
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(Figure 1d). CFR and MCF were similarly affected by HES
130/0.4, and there was no evidence of compound induced
fibrinolysis (data not shown). Although we observed a trend for
increased effects of HES 200/0.5, none of these effects was
significantly different from those observed with HES 130/0.4
(Figure 1a-d). FXIIIa activity did not significantly differ between
the blood samples diluted with saline, HES 130/0.4 or HES
200/0.5. At a 40% haemodilution rate, FXIIIa activities
amounted to 60.2% ± 8.4%, 62.7% ± 13.3% and 56.6% ±
15.7%, respectively.
Flow cytometry
Both HES 130/0.4 and 200/0.5 at a haemodilution rate of
40% significantly increased CD62P expression when plate-
lets were activated with either ADP or TRAP, but they did not
change the basal expression level in non-activated platelets. At
a haemodilution rate of 10%, neither HES preparation exerted
a significant effect on CD62P expression (Figure 2a). When
analysing the binding of fibrinogen to the platelet surface, sig-
nificant enhancements that amounted to about 25% and 40%
in ADP- or TRAP-activated platelets were observed by HES
200/0.5 but not by HES 130/0.5 (Figure 2b).
Figure 2
Effects of hydroxyethyl starch (HES) 130/0.4 and HES 200/0.5 on platelet activation markers and formation of platelet-leukocyte conjugates Effects of hydroxyethyl starch (HES) 130/0.4 and HES 200/0.5 on platelet activation markers and formation of platelet-leukocyte conjugates. After 
haemodilution of 10% (white) or 40% (grey) with either HES solution or saline (Con), platelets were activated by adenosine diphosphate (ADP) (5 
μM) or thrombin receptor-activating peptide (TRAP) (25 μM) for 5 minutes or remained inactivated (Basal). CD62P expression (a) and fibrinogen 
binding to platelets (b) as well as platelet-neutrophil (P-N) (c) and platelet-monocyte (P-M) (d) conjugates were determined by flow cytometry. The 
results are expressed as the relative numbers of platelets or leukocytes that were positive for CD62P or fibrinogen or the platelet-specific antigen 
CD42a. Data are given as mean ± standard error of the mean obtained from eight identical experiments. Significant differences between saline and 
HES 130/0.4 or HES 200/0.5: *P < 0.05, ** P < 0.005, *** P < 0.001. Significant differences between HES 130/0.4 and HES 200/0.5: §P < 0.05, 
§§P < 0.01.
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Figure 2c demonstrates the effect of the HES solutions on the
binding of platelets to neutrophils. In contrast to its effects on
the expression of CD62P and the binding of fibrinogen to
platelets, HES 130/0.4 had a greater effect on the binding of
platelets to neutrophils that is known to depend mainly on
platelet CD62P but also on platelet αIIbβ3 integrin [27]. Even
without platelet activation, we observed a slight but significant
increase of platelet-neutrophil conjugates in blood samples
diluted with HES 130/0.4 compared with HES 200/0.5 in
both 10% and 40% haemodilution rates. When platelets were
activated by ADP or TRAP, HES 130/0.4 at a 40% haemodi-
lution rate increased the number of platelet-neutrophil conju-
gates by a factor of about 1.5 when compared with controls
diluted with saline. At haemodilution rates of both 10% and
40%, the numbers of platelet-neutrophil conjugates were sig-
nificantly higher in samples treated with HES 130/0.4 when
compared with those treated with HES 200/0.5 (Figure 2c).
In contrast to HES effects on platelet-neutrophil conjugates,
we observed only marginal effects of HES on platelet-mono-
cyte conjugates (Figure 2d) and no effects on platelet-lym-
phocyte conjugate formation (data not shown). Significant
effects on platelet-monocyte conjugates were observed only
with HES 130/0.4. At a 40% haemodilution rate and platelet
activation by ADP, the number of conjugates was found to be
above those measured in control samples, and at a 10%
haemodilution rate, we found significantly more conjugates
with HES 130/0.4 compared with HES 200/0.5.
Discussion
The aim of our study was to test the hypotheses that HES
130/0.4 impairs haemostasis to a lesser degree than HES
200/0.5 and contributes to anti-inflammatory effects. Using
ROTEM analysis on blood samples diluted by 10% or 40%
from healthy volunteers, we observed a marked impairment of
clot formation haemostasis with both HES 130/0.4 and HES
200/0.5 compared with saline. However, there were no signif-
icant differences between 6% HES 130/0.4 and 10% HES
200/0.05. The lack of difference may correspond to the similar
molar concentrations of both HES solutions.
In line with our results, other investigators have found compa-
rable effects of HES 130/0.4 and 200/0.5 on haemostasis, in
particular in vitro clot formation as measured by ROTEM or
SONOCLOT® [28-31]. Jamnicki and colleagues [28] com-
pared HES 130/0.4 or HES 200/0.5 in preoperative blood
samples diluted to 30% or 60% from 80 patients scheduled
for elective surgery. The two HES solutions showed compara-
ble coagulation abnormalities. Konrad and colleagues [29]
investigated 33% and 66% dilutions of whole blood from
healthy volunteers with HES 70, HES 130 or HES 200 by
SONOCLOT and found that all HES solutions significantly
inhibited the early clotting stage compared with Ringer lactate
whereas HES 130 impaired clot formation and retraction less
than other HES solutions [29]. Thrombelastography in 45
patients performed after short-time infusions of HES 130,
HES 200 or 4% human albumin immediately after cardiac sur-
gery showed prolonged CFT and decreased MCF for both
HES solutions whereas no changes were observed after
human albumin [30]. In blood samples from volunteers diluted
to 10%, 20% and 30% with normal saline, HES 130 or HES
200, both HES solutions showed noticeably inhibitory effects
on platelet function whereas HES 200 had a greater effect on
blood cells and plasma separation [17]. With regard to previ-
ous studies that found comparable effects of HES 130 and
HES 200, none so far have compared the effects of the two
HES solutions on all of the measured variables in parallel in a
well-defined  in vitro system. Furthermore, we used
haemodilutions of 10% and 40% to comply more closely with
conditions in vivo, whereas others diluted their blood samples
to 55% [31] or 33% and 66% or used a different methodology
[29]. In our study, neither of the two HES solutions had signif-
icant effects on CT, whereas CFT was significantly prolonged
and MCF was decreased. The most pronounced effects of
HES solutions were observed on MCF in FIBTEM. This test
monitors the firmness of fibrin clots when the contribution of
platelets, in particular their interaction with fibrin(ogen) and
their contractile force, is removed. MCF dropped below the
lower level of normal (<9 mm) at a haemodilution rate of 10%,
which is indicative of high bleeding risk [32].
The mechanism for the inhibition of the fibrin network forma-
tion by HES is not yet clearly elucidated. So far, decreased
thrombin formation, impaired interaction between thrombin
and fibrinogen as well as an inhibition of FXIIIa activity have
been discussed [6,33]. With respect to FXIIIa, we could not
observe any effect of HES 200/0.5 or HES 130/0.4 on its
activity. Some authors have reported that administration of
HES resulted in an acquired fibrinogen deficiency that was
more severe than expected than haemodilution alone. Conse-
quently, fibrinogen supplementation was found to compensate
compromised haemostasis [18,33,34]. It is difficult to believe
that in vitro haemodilution with HES may result in a similar
fibrinogen-consuming process. However, one can speculate
that HES could directly interact with fibrinogen or fibrin and
thus inhibit the interaction with thrombin or FXIIIa or both.
Very recently, a discussion has been started whether 6% HES
130/0.4 or 130/0.42 dissolved in physiologically balanced
electrolyte solutions impairs haemostasis to a lesser extent
than HES dissolved in saline. With respect to balanced HES
solution, the supplementation of calcium ions seems to be of
special importance [35-37]. However, in an in vitro setting, dif-
ferences between the balanced solutions with and without cal-
cium ions on ROTEM were observed only at a haemodilution
rate of 50% [35,37]. At a 30% haemodilution rate, the reduc-
tion in MCF was similar to that which might be extrapolated
from the EXTEM tests in the present study.Critical Care    Vol 13 No 6    Sossdorf et al.
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It was reported elsewhere that the in vivo half-life time of HES
130/0.42 is shorter than that of HES 200/0.5, and this may
have an impact on their effects in clinical use [38]. However, it
was not the aim of our in vitro study to look for degradation-
dependent effects of both HES solutions. On the other hand,
it seems to be questionable whether preincubation of blood
samples with HES 130/0.42 or HES 200/0.5 for a different
length of time could mimic the in vivo degradation process,
including the accumulation of degradation products.
When added to blood samples, HES binds in a concentration-
dependent manner to the surface of platelets, and this is
believed to be responsible for the inhibition of platelet aggre-
gation [6,39]. Boldt and colleagues [37] reported a significant
inhibition of platelet aggregation in whole blood samples
measured by impedance aggregometry at a 30% haemodilu-
tion rate with both unbalanced and balanced 6% HES 130/
0.4 and 6% HES 130/0.42, respectively. Although using the
same experimental setup to measure platelet aggregation, the
same authors reported a significant inhibition of ADP- and col-
lagen-induced platelet aggregation at 50% haemodilution, but
not at 30% haemodilution, in a later communication [35].
Balanced HES 130/0.42 has been shown to increase the acti-
vation of the αIIbβ3 integrin on the platelet surface [36]. This
integrin is the platelet fibrinogen receptor, and its activation is
an essential prerequisite for platelet aggregation [40]. The
activation of the platelet fibrinogen receptor is in accordance
with our present data on increased fibrinogen binding to ADP-
or TRAP-activated platelets upon dilution of blood samples
with unbalanced HES 130/0.4 or HES 200/0.5 (Figure 2b).
Another marker of platelet activation is CD62P, which is local-
ised in resting platelets in intracellular granules and becomes
translocated to the platelet surface upon platelet activation.
CD62P is one of the molecules that mediate the interaction
between platelets and leukocytes, and platelets have been
shown to support inflammatory processes by CD62P-medi-
ated interaction with leukocytes [20,21,41]. We could show
that both HES 130/0.4 and HES 200/0.5 significantly
increased surface expression of CD62P when platelets were
activated by ADP or TRAP. The increase in platelet CD62P
expression was accompanied by an increase in the formation
of platelet-neutrophil conjugates, and this effect was seen not
only after platelet activation but also with non-activated plate-
lets. Interestingly, HES 130/0.4 was significantly more effec-
tive than HES 200/0.5 at increasing the number of platelet-
neutrophil conjugates. Compared with the platelet-neutrophil
interaction, the adhesion of platelets to monocytes was less
affected by HES but again HES 130/0.4 exerted stronger
effects than HES 200/0.5.
The findings of our in vitro study are limited because the anal-
yses were performed in blood samples drawn from volunteers
rather than from patients undergoing surgical interventions or
requiring acute volume therapy. However, the observation of
platelet activation for increased pro-inflammatory cell-cell
interactions with neutrophils is novel.
Conclusions
Our data obtained from in vitro experiments demonstrate that,
with respect to the impairment of haemostasis, HES 130/0.4
does not differ from HES 200/0.5. Furthermore, our results do
not support the claims that modified starch solutions may be
beneficial due to anti-inflammatory effects. HES 130/0.4 may
have a pro-inflammatory rather than an anti-inflammatory
effect, at least at the level of neutrophil-mediated processes.
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